AI assistant
IXICO PLC Earnings Release 2020
7723_er_2020-12-08_92d3d0b5-e250-4ce7-b6ca-85c0e53074df.html
Earnings Release
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8322H
IXICO plc
08 December 2020
IXICO plc
("IXICO" or the "Company")
IXICO contract with new large global pharma
IXICO selected by new large global pharma for orphan drug clinical trial
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has secured a contract for neuroimaging solutions with a new, large global pharmaceutical company. The Phase IIB trial will investigate an orphan drug designated clinical asset for the treatment of Huntington's disease.
Huntington's disease (HD) is a progressive and devastating neurodegenerative disorder for which no disease-modifying therapies currently exist. Orphan drug designations help biopharmaceutical sponsors undertake valuable investigations and develop treatments for rare and complex conditions such as HD. Since its inception in 2004, IXICO has had an extensive track record of delivering innovative neuroimaging solutions to support clients in optimising their pipelines for rare diseases.
This contract was included in management's expectations of performance for the current financial year but adds to the Company's strong order book.
Lammert Albers, Chief Commercial Officer of IXICO, commented: "We are delighted to be chosen to take part in this HD study to advance development of promising medical treatments for this devastating rare disease. This contract and new partnership will further endorse our breakthrough neuroimaging technologies with large pharma sponsors across the full spectrum of the drug development pathway."
For further information please contact:
| IXICO plc | +44 (0)20 3763 7498 | |||
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
||||
| Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
| Giles Balleny / Max Gould (Corporate Finance) | ||||
| Michael F Johnson / Russell Kerr (Sales | ||||
| Walbrook PR Ltd | +44 (0)20 7933 8780 | |||
| Paul McManus / Lianne Cawthorne / | [email protected] | |||
| Alice Woodings | ||||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
CNTFSEFWWESSELE